Demographics of the 20 studied patients with type 2 diabetes mellitus before starting SGLT2i therapies and the 24 healthy participants
| Parameters | Patients with type 2 diabetes (n=20) | Healthy control (n=24) |
| Gender (%) | 50% male, 50% female | 75% male, 25% female |
| Age (years), mean±SD | 65±10 (range 38–78) | 39±9 (range 21–65) |
| Weight (kg), mean±SD | 87±16 | 85±18 |
| BMI (kg/m2), mean±SD | 31±5 | 26±5 |
| Baseline HbA1c, % (mmol/mol), mean±SD | 7.5 (58)±0.9, range 6.6 (49)–9.8 (84) | n.a. |
| Duration of diabetes (years), mean±SD | 12±8 (range 1–30) | n.a. |
| Concomitant antidiabetic medication, n (%) | n.a. | |
| Only insulin | 3 (15) | |
| Insulin + OADs | 1 (5) | |
| Only OADs | 13 (65) | |
| No previous therapies | 3 (15) | |
| Cardiovascular diseases, n (%) | n.a. | |
| CHD | 4 (20) | |
| HTN | 18 (90) | |
| On RAAS inhibitors | 12 (60) | |
| No RAAS inhibitors | 8 (40) | |
| Hyperlipidemia, n (%) | 19 (95) | n.a. |
| Smoking status, n (%) | ||
| Never | 9 (45) | 13 (54.2) |
| Former | 8 (40) | 4 (16.6) |
| Current | 3 (15) | 7 (29.2) |
BMI, body mass index; CHD, coronary artery disease; HbA1c, glycated hemoglobin; HTN, arterial hypertension; n.a., not applicable; OADs, oral antidiabetic drugs; RAAS, renin-angiotensin-aldosterone system inhibitors; SGLT2i, sodium-glucose linked transporter-2 inhibitor.